Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 23% year-over-year as sales momentum continues Pre-clinical product revenue up 28% Cellular and Molecular Technologies (CMT) product revenue up 19% HOLLISTON, Mass., Nov.

HOLLISTON, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2021, before the market opens on November 3, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 25% year-over-year as sales momentum continues Cellular and Molecular (CMT) product revenue up 22% Pre-clinical product revenue up 20% Operating margins impacted by higher global supply

HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins Revenue up 14% as sales momentum from Q4’20 continues Pre-clinical product revenue up 24% Operating margin significantly improves year-over-year on GAAP and adjusted basis

HOLLISTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2021 before the market opens on May 6, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debt Revenue returns to pre-Covid19 levels on strong CRO/pharma sales Operating margin increased year-over-year on GAAP and an adjusted basis New debt facility significantly reduces

HOLLISTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2020 before the market opens on March 10, 2021, and will hold a conference call to discuss the results on March 10, 2021 at 8:00 a.m.

Improves liquidity and operating flexibility Significantly reduces borrowing costs Supports ongoing transformation to profitable growth platform HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its

HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference.